Pimavanserin tartrate (ACP-103) + Pimavanserin tartrate (ACP-103) + Placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
72
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Parkinson's Disease Psychosis

Conditions

Parkinson's Disease Psychosis

Trial Timeline

Jun 1, 2007 โ†’ Jul 1, 2009

About Pimavanserin tartrate (ACP-103) + Pimavanserin tartrate (ACP-103) + Placebo

Pimavanserin tartrate (ACP-103) + Pimavanserin tartrate (ACP-103) + Placebo is a phase 3 stage product being developed by Acadia Pharmaceuticals for Parkinson's Disease Psychosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00477672. Target conditions include Parkinson's Disease Psychosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00477672Phase 3Completed

Competing Products

20 competing products in Parkinson's Disease Psychosis

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
25
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
69
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
52
E2007EisaiPhase 3
77
ARICEPTEisaiPhase 3
77
PerampanelEisaiPhase 3
77
GPI 1485EisaiPhase 2
52
E2007EisaiPhase 3
77
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
77
perampanel + placeboEisaiPhase 2
52
Lemborexant + placeboEisaiApproved
85
Placebo + E2007 + E2007EisaiPhase 3
77
E2007 + E2007 + E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
2 mg perampanel + 4 mg perampanel + placebo comparatorEisaiPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 3
77